Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
Despite novel therapeutic agents, most multiple myeloma (MM) patients eventually relapse. Two large phase III trials have shown significantly improved response rates (RR) of lenalidomide/dexamethasone compared with placebo/dexamethasone in relapsed MM (RMM) patients. These results have led to the ap...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
25 April 2016
|
| In: |
BMC cancer
Year: 2016, Volume: 16 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-016-2321-2 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-016-2321-2 Verlag, kostenfrei, Volltext: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2321-2 |
| Author Notes: | Marc-Andrea Baertsch, Jana Schlenzka, Elias K. Mai, Maximilian Merz, Jens Hillengaß, Marc S. Raab, Dirk Hose, Patrick Wuchter, Anthony D. Ho, Anna Jauch, Thomas Hielscher, Christina Kunz, Steffen Luntz, Stefan Klein, Ingo G.H. Schmidt-Wolf, Martin Goerner, Martin Schmidt-Hieber, Peter Reimer, Ullrich Graeven, Roland Fenk, Hans Salwender, Christof Scheid, Axel Nogai, Mathias Haenel, Hans W. Lindemann, Hans Martin, Richard Noppeney, Katja Weisel and Hartmut Goldschmidt |
Search Result 1
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus len...
BioMed Central; Springer 2016
Article (Journal)
Book/Monograph
Online Resource